Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2017

Open Access 01-12-2017 | Research article

Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study

Authors: A. J. Landgren, L. T. H. Jacobsson, U. Lindström, T. Z. S. Sandström, P. Drivelegka, L. Björkman, E. Fjellstedt, M. Dehlin

Published in: Arthritis Research & Therapy | Issue 1/2017

Login to get access

Abstract

Background

Nephrolithiasis (NL) is known to be associated with gout, although there are few comparative studies on risk and risk factors for NL in gout compared to population cohorts. In this cohort study we investigated: (1) overall incidence of NL in gout (cases) and general population controls; (2) risk and risk factors (common comorbidities and medications) for first-time NL in cases and controls separately.

Methods

Cases (n = 29,968) and age-matched and sex-matched controls (n = 138,678) were identified from the regional healthcare database in western Sweden (VEGA). The analyzed risk factors (comorbidities and current medication use) for first-time NL, and socioeconomic factors were retrieved from VEGA and other national Swedish registers. For cases, follow up began on 1 January 2006 or on the first diagnosis of gout if this occurred later, and for controls on their index patient’s first diagnosis of gout. Follow up ended on death, emigration or 31 December 2012. Incidence rates (IR) per 1000 person-years and hazard ratios (HR) were calculated. The incidence calculations were performed for cases (regardless of prior NL) and their controls. HRs with first occurrence of NL as outcome were calculated only in those without previous NL.

Results

In cases there were 678 NL events (IR: 6.16 events per 1000 person-years (95% CI: 5.70–6.64) and in controls 2125 NL events (IR 3.85 events per 1000 person-years (95% CI: 3.69–4.02), resulting in an age-sex-adjusted incidence rate ratio of 1.60 (95% CI:1.47–1.74).
Point estimates for predictive factors were similar in cases and controls, except for a significant interaction for losartan which increased the risk of NL only in controls (HR = 1.49 (95% CI: 1.03–2.14). Loop diuretics significantly decreased the risk of NL by 30–34% in both cases and controls. Further significant predictors of NL in gout cases were male sex, diabetes and obesity and in controls male sex and kidney disease.

Conclusions

The risk (age and sex adjusted) of NL was increased by 60% in cases compared to controls. None of the commonly used medications increased the risk of NL in gout patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661–7.PubMedCrossRef Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661–7.PubMedCrossRef
2.
go back to reference Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136–41. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136–41.
3.
go back to reference Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin N Am. 2014;40(2):155–75.CrossRef Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin N Am. 2014;40(2):155–75.CrossRef
4.
go back to reference Dehlin M, Drivelegka P, Sigurdardottir V, Svärd A, Jacobsson LTH. Incidence and prevalence of gout in Western Sweden. Arthritis Res Ther. 2016;18(1):1–7.CrossRef Dehlin M, Drivelegka P, Sigurdardottir V, Svärd A, Jacobsson LTH. Incidence and prevalence of gout in Western Sweden. Arthritis Res Ther. 2016;18(1):1–7.CrossRef
5.
go back to reference Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002;40(1):37–42.PubMedCrossRef Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002;40(1):37–42.PubMedCrossRef
7.
go back to reference Yu T, Gutman AB. Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med. 1967;67(6):1133–48.PubMedCrossRef Yu T, Gutman AB. Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med. 1967;67(6):1133–48.PubMedCrossRef
8.
go back to reference Lieske JC, Pena de la Vega SL, Slezak JM, Bergstralh EJ, Leibson CL, Ho KL, Gettman MT. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int. 2006;69(4):760–4. Lieske JC, Pena de la Vega SL, Slezak JM, Bergstralh EJ, Leibson CL, Ho KL, Gettman MT. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int. 2006;69(4):760–4.
9.
go back to reference Amato M, Lusini ML, Nelli F. Epidemiology of nephrolithiasis today. Urol Int. 2004;72 Suppl 1:1–5.PubMedCrossRef Amato M, Lusini ML, Nelli F. Epidemiology of nephrolithiasis today. Urol Int. 2004;72 Suppl 1:1–5.PubMedCrossRef
10.
go back to reference Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and epidemiological characteristics of urolithiasis in Japan: national trends between 1965 and 2005. Urology. 2008;71(2):209–13.PubMedCrossRef Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and epidemiological characteristics of urolithiasis in Japan: national trends between 1965 and 2005. Urology. 2008;71(2):209–13.PubMedCrossRef
11.
go back to reference Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2-3):e86–96.PubMedPubMedCentral Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2-3):e86–96.PubMedPubMedCentral
12.
go back to reference Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int. 2003;64(3):1022–6.PubMedCrossRef Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int. 2003;64(3):1022–6.PubMedCrossRef
13.
go back to reference Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current concepts and controversies. J Urol. 2002;168(4 Pt 1):1307–14.PubMedCrossRef Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current concepts and controversies. J Urol. 2002;168(4 Pt 1):1307–14.PubMedCrossRef
14.
15.
go back to reference Pak CY, Barilla DE, Holt K, Brinkley L, Tolentino R, Zerwekh JE. Effect of oral purine load and allopurinol on the crystallization of calcium salts in urine of patients with hyperuricosuric calcium urolithiasis. Am J Med. 1978;65(4):593–9.PubMedCrossRef Pak CY, Barilla DE, Holt K, Brinkley L, Tolentino R, Zerwekh JE. Effect of oral purine load and allopurinol on the crystallization of calcium salts in urine of patients with hyperuricosuric calcium urolithiasis. Am J Med. 1978;65(4):593–9.PubMedCrossRef
17.
go back to reference Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008;73(4):489–96.PubMedCrossRef Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008;73(4):489–96.PubMedCrossRef
18.
go back to reference Xu H, Zisman AL, Coe FL, Worcester EM. Kidney stones: an update on current pharmacological management and future directions. Expert Opin Pharmacother. 2013;14(4):435–47.PubMedPubMedCentralCrossRef Xu H, Zisman AL, Coe FL, Worcester EM. Kidney stones: an update on current pharmacological management and future directions. Expert Opin Pharmacother. 2013;14(4):435–47.PubMedPubMedCentralCrossRef
19.
go back to reference Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003;63(5):1817–23.PubMedCrossRef Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003;63(5):1817–23.PubMedCrossRef
20.
go back to reference Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005;68(3):1230–5.PubMedCrossRef Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005;68(3):1230–5.PubMedCrossRef
22.
go back to reference Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–62.PubMedCrossRef Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–62.PubMedCrossRef
23.
go back to reference Shahinfar S, Simpson RL, Carides AD, Thiyagarajan B, Nakagawa Y, Umans JG, Parks JH, Coe FL. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int. 1999;56(5):1879–85.PubMedCrossRef Shahinfar S, Simpson RL, Carides AD, Thiyagarajan B, Nakagawa Y, Umans JG, Parks JH, Coe FL. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int. 1999;56(5):1879–85.PubMedCrossRef
25.
go back to reference Lin CS, Lee WL, Hung YJ, Lee DY, Chen KF, Chi WC, Chang SC. Prevalence of hyperuricemia and its association with antihypertensive treatment in hypertensive patients in Taiwan. Int J Cardiol. 2012;156(1):41–6.PubMedCrossRef Lin CS, Lee WL, Hung YJ, Lee DY, Chen KF, Chi WC, Chang SC. Prevalence of hyperuricemia and its association with antihypertensive treatment in hypertensive patients in Taiwan. Int J Cardiol. 2012;156(1):41–6.PubMedCrossRef
26.
go back to reference Choi HK, Soriano LC, Zhang Y, Rodriguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ (Clinical research ed). 2012;344:d8190. Choi HK, Soriano LC, Zhang Y, Rodriguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ (Clinical research ed). 2012;344:d8190.
27.
go back to reference Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, Elisaf MS. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148(4):635–40.PubMedCrossRef Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, Elisaf MS. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148(4):635–40.PubMedCrossRef
28.
go back to reference Harvengt C, Heller F, Desager JP. Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. Artery. 1980;7(1):73–82.PubMed Harvengt C, Heller F, Desager JP. Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. Artery. 1980;7(1):73–82.PubMed
29.
go back to reference Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63–70.PubMedCrossRef Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63–70.PubMedCrossRef
30.
go back to reference Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:90.PubMedPubMedCentralCrossRef Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:90.PubMedPubMedCentralCrossRef
31.
go back to reference Statistiska C. Folkmängden efter region, civilstånd, ålder och kön. År 1968 - 2014 www.scb.se. 2012. Statistiska C. Folkmängden efter region, civilstånd, ålder och kön. År 1968 - 2014 www.​scb.​se. 2012.
32.
go back to reference Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.PubMedPubMedCentralCrossRef Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.PubMedPubMedCentralCrossRef
33.
go back to reference Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75(1):210–7.PubMedCrossRef Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75(1):210–7.PubMedCrossRef
34.
go back to reference Marchini GS, Sarkissian C, Tian D, Gebreselassie S, Monga M. Gout, stone composition and urinary stone risk: a matched case comparative study. J Urol. 2013;189(4):1334–9.PubMedCrossRef Marchini GS, Sarkissian C, Tian D, Gebreselassie S, Monga M. Gout, stone composition and urinary stone risk: a matched case comparative study. J Urol. 2013;189(4):1334–9.PubMedCrossRef
35.
go back to reference Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315(22):1386–9.PubMedCrossRef Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315(22):1386–9.PubMedCrossRef
36.
go back to reference Dehlin M, Ekstrom EH, Petzold M, Stromberg U, Telg G, Jacobsson LT. Factors associated with initiation and persistence of urate-lowering therapy. Arthritis Res Ther. 2017;19(1):6.PubMedPubMedCentralCrossRef Dehlin M, Ekstrom EH, Petzold M, Stromberg U, Telg G, Jacobsson LT. Factors associated with initiation and persistence of urate-lowering therapy. Arthritis Res Ther. 2017;19(1):6.PubMedPubMedCentralCrossRef
37.
go back to reference Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis. 2005;64(2):267.PubMedPubMedCentralCrossRef Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis. 2005;64(2):267.PubMedPubMedCentralCrossRef
38.
go back to reference Kuo C-F, Grainge MJ, See L-C, Yu K-H, Luo S-F, Zhang W, Doherty M. Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther. 2015;17(1):13.PubMedPubMedCentralCrossRef Kuo C-F, Grainge MJ, See L-C, Yu K-H, Luo S-F, Zhang W, Doherty M. Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther. 2015;17(1):13.PubMedPubMedCentralCrossRef
39.
go back to reference Reilly RF, Peixoto AJ, Desir GV. The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. Clin J Am Soc Nephrol. 2010;5(10):1893–903.PubMedCrossRef Reilly RF, Peixoto AJ, Desir GV. The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. Clin J Am Soc Nephrol. 2010;5(10):1893–903.PubMedCrossRef
40.
go back to reference Zomorrodi A, Golivandan J, Samady J. Effect of diuretics on ureteral stone therapy with extracorporeal shock wave lithotripsy. Saudi J Kidney Dis Transpl. 2008;19(3):397–400.PubMed Zomorrodi A, Golivandan J, Samady J. Effect of diuretics on ureteral stone therapy with extracorporeal shock wave lithotripsy. Saudi J Kidney Dis Transpl. 2008;19(3):397–400.PubMed
41.
go back to reference Dehlin M, Stasinopoulou K, Jacobsson L. Validity of gout diagnosis in Swedish primary and secondary care - a validation study. BMC Musculoskelet Disord. 2015;16:149.PubMedPubMedCentralCrossRef Dehlin M, Stasinopoulou K, Jacobsson L. Validity of gout diagnosis in Swedish primary and secondary care - a validation study. BMC Musculoskelet Disord. 2015;16:149.PubMedPubMedCentralCrossRef
42.
go back to reference Jakobsen AK, Jacobsson LT, Patschan O, Askling J, Kristensen LE. Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects. PLoS One. 2014;9(11), e113602.PubMedPubMedCentralCrossRef Jakobsen AK, Jacobsson LT, Patschan O, Askling J, Kristensen LE. Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects. PLoS One. 2014;9(11), e113602.PubMedPubMedCentralCrossRef
43.
go back to reference Dawson CH, Tomson CR. Kidney stone disease: pathophysiology, investigation and medical treatment. Clin Med (Lond). 2012;12(5):467–71.CrossRef Dawson CH, Tomson CR. Kidney stone disease: pathophysiology, investigation and medical treatment. Clin Med (Lond). 2012;12(5):467–71.CrossRef
44.
go back to reference Moe OW. Kidney stones: pathophysiology and medical management. Lancet (London, England). 2006;367(9507):333–44. Moe OW. Kidney stones: pathophysiology and medical management. Lancet (London, England). 2006;367(9507):333–44.
Metadata
Title
Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study
Authors
A. J. Landgren
L. T. H. Jacobsson
U. Lindström
T. Z. S. Sandström
P. Drivelegka
L. Björkman
E. Fjellstedt
M. Dehlin
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2017
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-017-1376-z

Other articles of this Issue 1/2017

Arthritis Research & Therapy 1/2017 Go to the issue